Treatment progress of relapsed/refractory Hodgkin lymphoma / 白血病·淋巴瘤

Hodgkin lymphoma (HL) is a curable malignancy for most patients, while the treatment of relapsed and refractory (R/R) HL is still facing severe challenges. In the 60th American Society of Hematology (ASH) Annual Meeting, many researches reported the latest development of the treatment of R/R HL. For chemosensitive patients, autologous stem cell transplantation after high-dose of salvage chemotherapy still remains the standard treatment method. The emerging of antibody drug conjugate, inhibitors of programmed death-1, chimeric antigen receptor T-cell immunotherapy and the combinations of multiple drugs have brought an increasing options for R/R HL treatment. This paper reviews the progress of R/R HL therapy.